Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. by Sheng, Z. M. et al.
British Journal of Cancer (1996) 73, 144-147
fft (C3 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
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Summary A total of 80 primary human breast carcinoma DNAs were analysed for loss of heterozygosity
(LOH) on the long arm of chromosome 6, using microsatellite markers whose location has been defined
physically and by linkage analysis. Loss of heterozygosity was observed in 38 of 80 (48%) tumours that were
informative for at least one locus. The analysis revealed partial or interstitial deletions of chromosome 6q.
Detailed mapping of chromosome 6q in these tumour DNAs identified two and perhaps three commonly
deleted regions. One of these is located between markers D6S251 and D6S252 (6q14-q16.2), another between
D6S268 and D6S261 (6q16.3-q23) and a third between D6S287 and D6S270 (6q22.3-q23.1).
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Cytogenetic (Dutrillaux et al., 1990; Lu et al., 1993;
Thompson et al., 1993; Trent et al., 1985, 1993) and
molecular analyses (reviewed in Callahan et al., 1993) of
primary human breast carcinomas have documented fre-
quently occurring genetic alterations that take place during
the evolution of tumour development. It is thought that these
mutations either inactivate normal growth controls or give
the tumour some selective advantage. At the molecular level,
loss of heterozygosity (LOH) is the most frequent type of
genetic alteration in primary human breast tumours
(Callahan et al., 1993). LOH at specific chromosomal loci
has been taken as evidence for the presence of putative
tumour-suppressor genes within the affected regions
(Knudson, 1989). In sporadic primary human breast
carcinomas LOH has been detected on at least 12 different
chromosome arms (Callahan et al., 1993). However only in
the case of chromosome l7pl3 has the target gene for LOH
(TP53) been identified (Hollstein et al., 1991). Generally one
allele of the target gene is lost and the remaining allele
contains a nonsense or missense mutation. The involvement
of chromosome 6q in breast carcinomas has been noted in
cytogenetic analysis of primary tumours (Dutrillaux et al.,
1990; Lu et al., 1993; Thompson et al., 1993; Trent et al.,
1985, 1993). Similarly, molecular analysis of primary breast
tumour DNAs has shown that chromosome 6q is frequently
affected by LOH (Devilee et al., 1991). In this report, we
describe studies aimed at defining the location of putative
tumour-suppressor gene(s) on chromosome 6q in primary
breast tumour DNAs. We have screened 80 pairs of matched
breast tumour and normal DNAs using sequence-tag sites
(STSs) whose location has been defined by linkage analysis
and have constructed a detailed deletion map of this
chromosome arm.
Materials and methods
Thirty invasive ductal carcinomas (IDCs) of the breast and
matching peripheral lymphocytes were collected at the Centre
Rene Huguenin, Saint Cloud, France (tumour panel 1), and
another 50 pairs of IDCs and matched lymphocytes were
collected from University of Pisa, Pisa, Italy (tumour panel
2). Patients corresponding to each of the tumour panels had
received no prior therapy.
Genomic DNA was extracted and diluted to 100-
200 ng pl-'. Polymerase chain reaction (PCR) was per-
formed with 100-200 ng of template DNA, 10 mM Tris-
HCl, 1.5 mM magnesium chloride, 50 mM potassium chloride,
gelatin 0.1 mg ml-', 200 g1M each dNTP, 0.5 U Taq
polymerase (Boehringer Mannheim) and 50 pmol of each
primer in a total volume of 10 1l or 25 Ml. The PCR product
was identified by end labelling primers with [y-32P]ATP or the
PCR product was internally labelled with [c_-32P]dCTP. All
PCR reactions were performed on a Perkin Elmer Cetus PCR
system with denaturation for 6 min at 94°C followed by 30
cycles of denaturation at 94°C for 1 min, annealing
temperature (Table 1) for 1 min, and extension at 72°C for
1 min. The primers for the STS loci that were examined
(Gyapa et al., 1994; Volz et al., 1994), their annealing
temperatures and the references describing them are shown in
Table I.
The PCR products were diluted with loading buffer (95%
formamide, 20 mM EDTA, 0.05% bromophenol blue and
0.05% xylene cyanol), heat denatured and rapidly cooled.
Samples were run in pairs (tumour and lymphocyte PCR
product from the same patient) on a denaturing gel (7%
acrylamide, 32% formamide, 6 M urea, 1 xTBE) at a
constant 30-35 W. After electrophoresis the gel was
transferred to 3MM Whatman paper and autoradiography
performed with Kodak X-Omat AR film at - 70'C. When
the signal of an allele in tumour DNA was less than 50% of
intensity observed in matching normal DNA from a
heterozygous patient, LOH was considered to have occurred
(Bieche et al., 1993).
Results
Preliminary results obtained at 6 loci (D6S254, D6S251,
D6S252, D6S249, ARGI and D6S255) on chromosome 6q in
30 breast tumour DNAs (tumour panel 1) suggested that
LOH on this arm of chromosome 6 was a frequent event
(Table II). LOH was detected in nine tumour DNAs. In three
tumour DNA samples all informative loci were affected by
LOH. Six other tumour DNAs had loss of one allele at
D6S251 or D6S252 or D6S249. However, the data set was
too small to determine with any precision the location of the
target region(s). Therefore, this study was extended to include
another 50 primary breast carcinoma DNAs (tumour panel 2)
with eight additional microsatellite markers whose localisa-
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Table I STS loci and primers on chromosome 6q
Annealing
temperature
LocusISTS (OC) Primers (5'-3') References
D6S254 55 AGAGAGGCTGAAGACCAATC Wilkie et al. (1993)
TCCCATAGCTACAAGCCACT
D6S286 55 GGCCCAGCATCACCCCTAAT Gyapa et al. (1994)
CCAATCGTGCATCCCAAAGA
D6S284 53 CATGGCTGTCTATCAAACCC Gyapa et al (1994)
AAGCATTTGTGTGGCTCTTG
D6S251 55 TTCCTAACCAGGTTTCAATG Wilkie et al (1993)
ATATTTTTAAAGTAAGTTGCVAC
D6S252 55 TGAAAGGAAAGTCCTGCTTC Wilkie et al. (1993)
ATGGCTCAGGATTCACATTG
D6S249 55 TTCTATTTCTGAAGGTGAACTA Wilkie et al. (1993)
ATAGTTACCATCAGTCACTG
D6S268 50 CTAGGTGGCAGAGCAACATA Gyapa et al. (1994)
AAAAGGAGGTCATTTTAATCG
D6S302 50 TTCACAATGACAAGTCCAATACACG Gyapa et al. 1994)
TTCTTTAGGATAAGCCAATACACG
D6S261 50 GTGAAACCCTGTCTCACTGC Gyapa et al. (1994)
GGATTTATAGTGACCATGCCA
D6S287 50 ATATTAGTGCCTTATGCTTCTG Gyapa et al. (1994)
AAATTGGATATTCATGCTTG
D6S262 50 ATTCTTACTGCTGGAAAACCAT Gyapa et al. (1994)
GGAGCATAGTTACCCTTAAAATC
D6S270 55 GTGTAACTGATCTGAATGGTTCC Gyapa et al. (1994)
GTAGTGAAGCCTGGATGTGG
ARGI 55 CTACATATTTCTAAATACATGC Wilkie et al. (1993)
ACTTAGTAGTTTTAAGCAGGA
D6S255 55 TCAGCATCAAGGTACTTGAG Wilkie et al. (1993)
TTAGTGCCCTATGCAAGGCA
Table II LOH on chromosome 6q in breast tumour panel 1
Regional LOH/inf Tumour DNA No.
assignment Locus n (%) 14 21 22 25 48 51 54 55 66
6ql3 D6S254 30 0/5 (0) NI NI NI H NI NI NI NI NI
6ql4-q16.2 D6S251 30 6/28 (21) D H D H D D D H D
D6S252 30 4/16 (25) NI D NI NI H D NI D D
6ql6.3-q21 D6S249 30 5/14 (36) D NI H D H D D NI D
6q22.3-q23.1 ARG 30 2/12 (17) NI D NI NI H NI NI H D
6q25.2 D6S255 30 3/9 (33) D D NI NI NI NI H NI D
The genotypes of nine tumour DNA samples from tumour panel 1 at STS markers between D6S254 and
D6S255 that were tested and their regional locations are listed. The genetic order ofthe STS loci is according to
published linkage studies (Gyapa et al., 1994; Volz et al., 1994). n, total number of tumour DNA samples
examined for each marker; LOH/inf., fraction oftumours from informative patients that showed LOH at each
marker; the number in parenthesis is the percentage oftumours having LOH at each locus; D, LOH; H, STS loci
that were informative but unaffected; NI, STS loci that were not informative.
tion and order were determined by linkage analysis (Gyapa et
al., 1994; Volz et al., 1994).
In this second set of 50 breast tumour DNA samples, all
were informative for at least one locus and of these 29 (58%)
had LOH at one or more loci. The frequency of LOH at the
different STSs loci on chromosome 6q for tumour panel 2 is
shown in Table III. Autoradiographs of two tumour DNA
samples from tumour panel 2, each at three different STS
loci, is shown in Figure 1. Sample 281 had LOH at D6S286
and D6S251 but was informative and unaffected at D6S252.
These results taken together with those summarised in Table
III for tumour DNA samples 127, 28, 91, 304, 263 and 49 are
consistent with the presence of a tumour-suppressor gene
located in the 10 cM interval between D6S284/D6S286 and
D6S252 on chromosome 6ql4-ql6.2 (region 1). If tumour
DNA 82 is also considered the size of region 1 may be
further reduced to the 1.1 cM interval between D6S284/
D6S286 and D6S251.
Shown in Figure 1 are autoradiographs of tumour DNA
sample 82, which indicate that a second region of
chromosome 6q is independently affected by LOH. In this
tumour DNA, D6S268 and D6S261 are both informative and
unaffected whereas LOH was detected at D6S302. The results
summarised in Table III for tumour DNA samples 63, 224
and 204 are also consistent with the presence of a tumour-
suppressor gene located in the 5.2 cM interval between
D6S268 and D6S261 (region 2). Evidence for a third region
affected by LOH was found in tumours DNAs 204, 99, 208,
49, 114 and 83 (Table III). In these tumour DNA samples
D6S262 was affected by LOH, whereas the more centromeric
locus D6S287 was informative and unaffected. The telomeric
boundary of this region could be D6S270 since in tumour
DNAs 204 and 99 it was unaffected by LOH.
Several of the tumour DNAs were remarkable in that
more than one region of chromosome 6q was affected by
LOH. For instance tumour DNA samples 82, 263 and 281
exibited independent LOH of regions 1 and 2 whereas in
tumour DNA 204 regions 2 and 3 were independently
affected by LOH (Table III). Similarly in tumour DNA
sample 208 regions 1 and 3 were affected by LOH and in
sample 49, each of the three regions were independently
affected by LOH. Cytogenetic analysis of metastatic breast
carcinomas have also identified tumours with multiple
chromosome 6 alterations (Dutrillaux et al., 1990; Lu et al.,
1993; Thompson et al., 1993; Trent et al., 1993). In several
cases it was not possible to unambiguously determine whichLOH on chromosome 6q In breast tumour DNAs
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Fugwe 1 Autoradiographs ofthree tumour DNA samples having
LOH at STS markers on chromosome 6q. (a) The STS markers
were D6S286, D6S251 and D6S252. Arrows mark the deleted
allele at D6S286 and D6S251 in tumour DNA 281. (b) The STS
markers were D6S268, D6S302, D6S261. The arrow marks the
deleted aLlele of D6S302 in tumour DNA 82. The autoradiograph
for tumour and lymphocyte DNA at D6S268 represent different
exposures of the same gel.
region was the target for LOH. Thus in tumour DNAs 351
and 86 either region 1 or region 2 could have been the target
for LOH. Similarly, in samples 178, 394, 125, 272, 14, 150,
and 62 either region 2 or region 3 could contain the target
tumour-suppressor gene.
Discussion
Our results confirm the findings of Devilee et al. (1991) that
LOH on chromosome 6q is a frequent event in primary
human breast carcinomas. They detected LOH at MYB and,
or D6S37 in 50% of the tumour DNA samples. The MYB
locus is 5 cM telomeric of D6S270 (Gyapa et al., 1994; Volz
et al., 1994) and D6S37 is at the distal end of chromosome
6q. Our study extends their results by defining three regions
of chromosome 6q that are independently affected by LOH.
During the course of our work Orphanos et al. (1995)
reported two regions on chromosome 6q that are affected by
LOH in human breast tumour DNAs. One of these spans
6ql3-q21 and probably corresponds to regions 1 and 2 in
our data set. The second region in their study was located at
6q21-q27 and is distal to region 3 in our study. LOH on
chromosome 6q is not unique to breast carcinomas, it has
been detected in 40% of melanomas in the region of 6ql6-
q23 (Millikin et al., 1991). Similarly, Saito et al. (1992) found
that 51% of ovarian carcinomas had LOH at one or more of
nine loci on chromosome 6q24-q27. In this study the
commonly deleted region was 6q26-q27.
At the present time there are few, if any, candidate target
genes for LOH on chromosome 6q. However, Negrini et al.
(1994) have shown that microcell-mediated transfer of
chromosome 6 into the human breast tumour cell line
MDA-MB-231 inhibits its tumorgenicity in BALB/c-nu,nu
mice as well as causing the cells to age in culture. An analysis
of polymorphic loci which identifies the portions of the
transferred chromosome 6 that were retained in the cell line,
suggested that at least two functional regions of 6q are
important for tumour suppression. One functional region was
at the distal end of 6q near D6S48. Based on current linkage
maps of chromosome 6q (Gyapa et al., 1994; Volz et al.,
1994) the second functional region is located between the
CNR locus (6ql4-ql5) and D6S310 (9 cM telomenrc of
D6S270, see Table III). This second functional region is
consistent with regions 1, 2 and possibly 3 presented in our
study. Clearly the development of a physical map of the
polymorphic STSs loci on chromosome 6q should lead to
further definition of the regions affected by LOH and to the
target gene(s) in primary breast tumours.
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